IN THE CLAIMS

1 – 19 (Cancelled)

20. (New) A pharmaceutical formulation comprising an early-stage mevalonate pathway blocker and a bisphosphonate.

21. (New) The pharmaceutical formulation of claim 20, wherein the early-stage mevalonate pathway blocker is an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase.

22. (New) The pharmaceutical formulation of claim 20, wherein the early-stage mevalonate pathway blocker is a statin.

23. (New) The pharmaceutical formulation of claim 22, wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, fluvastatin, mevinolin, and a combination thereof.

24. (New) The pharmaceutical formulation of claim 20 wherein the bisphosphonate is a nitrogen containing bisphosphonate.

25. (New) The pharmaceutical formulation of claim 24, wherein the bisphosphonate is selected from the group consisiting of pamidronate, dimethyl pamidronate, alendronate, ibandronate, risedronate, zoledronate, and a combination thereof.

26. (New) The pharmaceutical formulation of claim 20 further comprising a carrier.

27. (New) A method for treating a condition treatable with a bisphosphonate, the bisphosphonate associated with an acute phase response in a patient, the method comprising administering an effective amount of an early-stage mevalonate pathway blocker thereto.

28. (New) The method of claim 27, wherein the patient is human.

29. (New) The method of claim 27, wherein the patient is non-human.

30. (New) The method of claim 29, wherein the non-human patient is selected from the group consisting of a horse and a cat.

31. (New) The method of claim 27 wherein the condition is selected from the group consisting of osteoporosis, Paget's disease, skeletal metastases, fibrous dysplasia, Charcot's arthropathy, sympathetic dystrophy, pachydermic periostosis, aseptic osteomyelitis, multiple myeloma, hypercalcaemia, atherosclerosis, and diabetes.

32. (New) The method of claim 27, wherein the early-stage mevalonate pathway blocker is an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase.

33. (New) The method of claim 27, wherein the early-stage mevalonate pathway blocker is a statin.

34. (New) The method of claim 33, wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, fluvastatin, mevinolin, and a combination thereof.

35. (New) The method of claim 27 wherein the bisphosphonate is a nitrogen containing bisphosphonate.

36. (New) The method of claim 35, wherein the bisphosphonate is selected from the group consisiting of pamidronate, dimethyl pamidronate, alendronate, ibandronate, risedronate, zoledronate, and a combination thereof.

37. (New) A kit comprising:

a first medicament comprising an early-stage mevalonate pathway blocker, and

a second medicament comprising bisphosphonate,

together with an indication that the first medicament should be taken no later than the second medicament.

38. (New) The kit of claim 37, wherein the indication is that the first medicament should be taken from several hours to several days before taking the second medicament.

39. (New) The kit of claim 37, wherein the medicaments are provided in a form suitable for oral administration.

40. (New) The kit of claim 37, wherein the early-stage mevalonate pathway blocker is an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase.

41. (New) The kit of claim 37, wherein the early-stage mevalonate pathway blocker is a statin.

42. (New) The kit of claim 41, wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, fluvastatin, mevinolin, and a combination thereof.

43. (New) The kit of claim 37 wherein the bisphosphonate is a nitrogen containing bisphosphonate.

44. (New) The kit of claim 43, wherein the bisphosphonate is selected from the group consisiting of pamidronate, dimethyl pamidronate, alendronate, ibandronate, risedronate, zoledronate, and a combination thereof.